Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Gilligan's Island Sell Setup | Bearish Swing Setup | -59.27% | |
Crossed Above 20 DMA | Bullish | -59.27% | |
Crossed Above 200 DMA | Bullish | -59.27% | |
Crossed Above 50 DMA | Bullish | -59.27% | |
MACD Bullish Signal Line Cross | Bullish | -59.27% | |
New Uptrend | Bullish | -59.27% | |
Pocket Pivot | Bullish Swing Setup | -59.27% | |
Volume Surge | Other | -59.27% | |
NR7 | Range Contraction | -59.27% | |
Narrow Range Bar | Range Contraction | -59.27% |
Alert | Time |
---|---|
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. |
Get a Trading Sidekick!
- Earnings date: 03/21/2024
Biohaven Pharmaceutical Holding Company Ltd. Description
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Neuroscience Organic Compounds Chemical Compounds Neurodegenerative Diseases Glutamate Neurotransmitters N Methyl D Aspartic Acid Riluzole
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 62.21 |
52 Week Low | 12.35 |
Average Volume | 1,203,559 |
200-Day Moving Average | 32.84 |
50-Day Moving Average | 50.44 |
20-Day Moving Average | 56.37 |
10-Day Moving Average | 56.68 |
Average True Range | 3.24 |
RSI (14) | 57.98 |
ADX | 31.76 |
+DI | 29.25 |
-DI | 16.05 |
Chandelier Exit (Long, 3 ATRs) | 52.48 |
Chandelier Exit (Short, 3 ATRs) | 55.58 |
Upper Bollinger Bands | 61.98 |
Lower Bollinger Band | 50.76 |
Percent B (%b) | 0.56 |
BandWidth | 19.91 |
MACD Line | 1.89 |
MACD Signal Line | 2.37 |
MACD Histogram | -0.4799 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 61.30 | ||||
Resistance 3 (R3) | 60.84 | 58.95 | 60.58 | ||
Resistance 2 (R2) | 58.95 | 57.86 | 59.18 | 60.34 | |
Resistance 1 (R1) | 57.99 | 57.19 | 58.47 | 58.45 | 60.11 |
Pivot Point | 56.10 | 56.10 | 56.35 | 56.33 | 56.10 |
Support 1 (S1) | 55.14 | 55.01 | 55.62 | 55.60 | 53.93 |
Support 2 (S2) | 53.25 | 54.34 | 53.48 | 53.70 | |
Support 3 (S3) | 52.29 | 53.25 | 53.46 | ||
Support 4 (S4) | 52.75 |